Country Report: Egypt
Pharmaceutical Executive
In the middle of new reforms, and with its political turmoil well in the past, Egypt is striving to open the door to a brave new era of healthcare provision, where improving public healthcare has been assigned priority status.
Gaining Traction
After successive revolutions and a period of political turmoil between 2011 and 2013, Egypt is currently enjoying a period of relative stability, with President Abdel Fattah El-Sisi officially taking power in 2014 and gaining reelection in a landslide victory in 2018. Under his auspices, an extensive set of economic reforms has commenced: most notably the 2016 decision to unpeg the national currency from the US dollar so as to float the Egyptian Pound, and the introduction of a new investment law in 2017.
Moreover, improving public healthcare has been assigned priority status, with wellness considered one of the pillars of the cabinet’s human capital development goals. Objectives here include the launch of the Universal Healthcare Act and various national campaigns, such as the 100 Million Seha campaign to eradicate hepatitis C in the country. In the light of these reforms, Egypt is striving to open the door to a brave new era of healthcare provision, with all the fresh businesses opportunities that this presupposes.
To view the full article on Egypt’s life sciences and healthcare markets, produced by Focus Reports and featured in Pharm Exec's July 2019 issue, click
here(cycle down to page 38).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
